Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

32 items

Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.

Funded Biomarker Disease Site: Endometrium

Biomarker: P53, PR, ER

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma.

Funded Biomarker Disease Site: Head and Neck

Biomarker: PD-L1

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.

Funded Biomarker Disease Site: Bladder/ Urothelial

Biomarker: MLH1, MSH2, MSH6, PMS2

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Reflex testing on newly diagnosed tumours with uveal melanoma.

Funded Biomarker Disease Site: Ocular

Biomarker: GNAQ, GNA11

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Funded Biomarker Disease Site: Ovary

Biomarker: BRCA1, BRCA2

Testing Method:Panel

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Funded Biomarker Disease Site: Breast

Biomarker: ESR1, PIK3CA

Testing Method:Panel

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Funded Biomarker Disease Site: Lung

Biomarker: Acquired EGFR T790M

Testing Method:Sequencing

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Funded Biomarker Disease Site: Hepatobiliary

Biomarker: FGFR2

Testing Method:Sequencing

Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Funded Biomarker Testing

Funded Biomarker Testing

Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.

Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma.

Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.

Reflex testing on newly diagnosed tumours with uveal melanoma.

Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Testing on advanced/metastatic breast cancer where directed therapy is being considered.

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered

Pages